ABSTRACT ONO-1301 
Introduction
ONO-1301 is a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity. Unlike prostacyclin, ONO-1301 does not possess a five-membered ring or allylic alcohol in its molecular structure, making it more biologically and chemically stable. Its inhibitory effect on thromboxane synthetase is mediated by binding of thromboxane synthase to the 3-pyridine moiety and a carboxylic acid group in ONO-1301 [1] .
Prostacyclin (PGI 2 ), produced in the vascular endothelium, is a potent vasodilator and a strong inhibitor of platelet aggregation [2] [3] [4] . Thromboxane A 2 (TXA 2 ) on the other hand, although also a powerful vasodilator, promotes platelet aggregation [3] . An imbalance of PGI 2 and TXA 2 may therefore result in vasospasm [5] . Experimental and clinical data have shown that PGI 2 may reduce vasoconstriction elicited by subarachnoid hemorrhage [6] [7] [8] [9] , and beneficial effects of low-dose prostacyclin infusion (0.5 ng/kg/min) have been reported in severe traumatic brain injury [10, 11] .
A prostaglandin analogue, beraprost sodium, is known to significantly increase tail nerve conduction velocity (NCV) in rats with streptozotocin (STZ)-induced diabetes [12] . In a previous study, we reported that ONO-1301-loaded PLGA microspheres improved delayed NCV in the lower limb of STZ-induced diabetic rats [13] , while in other studies, it has been reported that ONO-1301 improves pulmonary hypertension [14, 15] , and attenuates pulmonary fibrosis [16] . However, the neuroprotective effect of ONO-1301 has not been clarified.
The purpose of this study was to investigate the neuroprotective effect of ONO-1301 in rats subjected to cerebral ischemia. We used a modification of the stroke model developed by Pulsinelli and Brierley [17] , termed cerebral ischemia model. Firstly, plasma level of radio-activity derived from 14 C-ONO-1301 was measured in rats treated orally (p.o.) with 1 and 10 mg/kg 14 C-ONO-1301, in order to determine the pharmacokinetics of ONO-1301 in vivo. Then we examined the effect of 42 days post-ischemic ONO-1301 treatment on neuronal damage, expression of PCNA-positive cells and activated astrocytes in the hippocampal CA1 region using cerebral ischemia model. In order to investigate the protective effect of ONO-1301 on physiological function, spatial learning was assessed using the Morris water maze (MWM) task.
Materials and Methods

Animals
Male Wistar rats weighing 250 -300 g were obtained from Charles River Japan Inc. (Hino, Japan), and were housed in groups of 4/5 animals per cage in a temperature-controlled room (23˚C ± 2˚C) with a relative humidity of 60% ± 10%. The lights were on from 7:00 to 19:00. The animals had free access to food (CRF-1, Oriental Yeast Co., Ltd., Tokyo, Japan) and water. Experiments were conducted between 9:00 and 17:00. All procedures regarding animal care and use were carried out according to the regulations of the Experimental Animal Care and Use Committee of Mukogawa Women's University. All experiments conformed to the guidelines on the ethical use of animals of the Japanese Government Notification, and all efforts were made to minimize both the number of animals used and their suffering.
Cerebral Ischemia
Animals were subjected to cerebral ischemia according to a previously published method [18] . Rats were anaesthetized with intraperitoneal (i.p.) sodium pentobarbital (35 mg/kg) and immobilized in a stereotaxic apparatus (Type SR-6; Narishige Scientific Instrument Laboratories, Tokyo, Japan). The bilateral arteries beneath the alar foramina of the first vertebra were electrocoagulated using a bipolar coagulator (MICRO-3D; Mizuho Industrial Co., Tokyo, Japan). The following day the common carotid arteries were compressed using a Schwartz vessel clip (1.7 × 8 mm jaw; World Precision Instrument, Sarasota, FL, USA) to each artery, and cerebral circulation was interrupted for 10 min. This was repeated once after a 1-min interval. Rats that did not demonstrate loss of their righting reflex during arterial occlusion were excluded from subsequent experiments.
Animals were randomly divided into seven groups: a sham-ischemia group treated with 0. counts. This specification was met for the sample aliquots that had radioactivity greater than 100 dpm. Scintillation counting data (cpm) were automatically corrected for counting efficiency using the external standardization technique and an instrument-stored quench curve generated from a series of sealed quenched standards.
Fixation and Processing of Tissue for Histology
Rats were killed by deep anaesthetization with pentobarbital (35 mg/kg, i.p.) and transcardial perfusion with cold heparinized saline, followed by perfusion of 4% paraformaldehyde. The brain was then removed from the skull and post-fixed overnight in paraformaldehyde, before being dehydrated and embedded in paraffin. Coronal sections 10-µm thick were made using a rotary microtome. For hippocampal morphology, a 3.3-mm section was taken from the bregma [19] .
Histological Examination
In order to assess cell damage in the hippocampus after cerebral ischemia, the number of surviving cells was counted in Nissl-stained hipocampal sections. Other representative coronal sections were stained with proliferating cell nuclear antigen (PCNA), or glial fibrillary acidic protein (GFAP). These sections were examined by light microscopy, and the neuronal density of CA1 neurons (per mm 2 ) in the stratum pyramidale measured. Immunohistochemical detection (PCNA and GFAP) of cell damage in paraffin-embedded brain sections was performed by the streptavidin-avitin-biotin-immunop-eroxidase complex method [20] . Briefly, 10-µm thin PCNAstained sections on poly-L-lysine-coated slides were deparaffinized and rehydrated. Endogenous peroxidase activity was blocked with 1% H 2 O 2 in 0.1 mol/L Tris-NaCl (pH 7.4) for 30 min. After incubation with 5% normal bovine serum albumin (BSA; Serologicals, GA, USA) for 1 h at 37˚C, sections were incubated overnight at 40˚C with primary antibody mouse anti-rat PCNA (Dako Cytmation, Glostrup, Denmark) in 1% BSA using a 1:50 dilution. Sections were then incubated with a biotinylated secondary antibody goat anti-mouse IgG (Dako Cytmation, Glostrup, Denmark) for 30 min at 37˚C at a 1:200 dilution.
This was followed by incubation with streptavidin peroxidase (1:100) for 1 h and subsequent chromogen development with 0.5% 3,3'-diaminobenzedrine tetrahydrochloride (DAB) and 0.33% H 2 O 2 in 0.5 mol/L TrisNaCl as substrate. The sections were counterstained with Harris Haematoxylin (H&E), then dehydrated, mounted, and used as a positive control.
In the GFAP staining, rabbit anti-rat GFAP (Dako Cytmation, Glostrup, Denmark) was used as primary antibody. A biotinylated goat anti-rabbit IgG (Dako Cytmation, Glostrup, Denmark) was used as secondary antibody.
Damage was scored in the CA1 according to the method of Freund et al. [21] : normal (score 0). No positive cells detected; mild (score 1), <20% positive cells; moderate (score 2), 20% -50% positive cells; severe (score 3), 50% -70% positive cells; very severe (score 4), >70% positive cells. The damage score (from 0 to 4) for each subfield was calculated as a mean of the damage score in all sections in which the subfield was present. The total hippocampal damage score was calculated as the sum of subfield damage scores.
MWM Task for Spatial Learning
The swimming pool (Neuroscience Inc.) was a circular water tank, 148 cm in diameter and 44 cm deep, which was modified according to Morris [22] . It was filled to a depth of 32 cm with clear water at a temperature of 23˚C ± 2˚C. The test was performed with the illumination of a 100-W bulb. A platform, 12 cm in diameter and 30 cm in height, was present inside the tank, its top surface being 0.5 cm below the surface of the water. The pool was located in a large test room, and surrounded by many cues external to the maze (e.g. the experimenter, ceiling lights, racks, etc.), which were visible from within the pool and could be used by the rat for spatial location. The positions of the cues were unchanged throughout the test period. The CCD camera, equipped with a personal computer, was used for behavioral analysis (AXIS-30, Neuroscience Inc).
Each rat received two trials daily for four consecutive days. A trial consisted of placing the rat by hand into the water facing the wall of the pool, at one of three starting positions (excluding the quadrant containing the platform). The pool was divided into sections (north: N, south: S, east: E, or west: W). The platform was located in a constant position in the middle of one quadrant and its location was the same for all rats. During each block of three trials, each rat started once at each of the three starting positions, but the sequence of the positions was selected at random. In each trial, the time taken to swim to the hidden platform was recorded; the cut-off time was 90 s. If a rat found the platform, it was permitted to remain there for 30 s. If a rat failed to find the platform within 90 s, the rat was forced to remain on the platform for 30 s. At the end of a trial, the rat was returned to its cage. The inter-trial interval time was approximately 30 min. The performance of the test animal in each trial was assessed by two parameters: swimming time and swimming distance, using the personal computer. Swimming speed was calculated by Swimming length (m) per Goal latency (s).
Statistical Analysis
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Results
Pharmacokinetic Study of ONO-1301 in
Intact Rats Inhibitory Activity in Rats Subjected to Cerebral Ischemia 10 mg/kg group were approximately 10-fold greater than the plasma those of 1 mg/kg group ( Table 1) . The time at which the maximal concentration occurred (T max ) was similar between 1 mg/kg and 10 mg/kg group. The elimination T 1/2 of 1 mg/kg group (8.9 ± 4.1 h) was greater than that of 10 mg/kg group (5.1 ± 1.7 h) ( Table  1 ; Figure 1 ). 
Effect of
Spatial Learning Using the MWM Task in Post-Ischemic Rats
The MWM task was carried out on the 14 days after the end of the 42 days ONO-1301 treatment period. The repeated measure one-way ANOVA for goal latency showed a significantly delayed goal latency between the sham-ischemic and vehicle-ischemic groups (F = 3.46, P < 0.01). The goal latency of 42 days ONO-1301-treated rats (10 mg/kg) was significantly improved compared with the vehicle-ischemic group (P < 0.01) with an average goal latency in eight time trials of: 42d Sham 42.5 ± 2.2 s, 42d Vehicle 58.4 ± 1.9 s, 42d ONO-1301 10 mg/kg 47.9 ± 2.3 s, and 34d ONO-1301 10 mg/kg 51.7 ± 2.2 s; Figure 6 (a). Furthermore, there was a significant difference between the swimming length of the shamischemic and vehicle-ischemic groups (F = 4.05, P < 0.01). The swimming length of 42 days ONO-1301 treated Inhibitory Activity in Rats Subjected to Cerebral Ischemia rats was significantly less than the vehicle-ischemic group (P < 0.01) with average swimming times in eight time trials of: 42d Sham 1068.9 ± 53.8 cm, 42d Vehicle 1500.7 ± 47.4 cm, 42d ONO-1301 10 mg/kg 1172.7 ± 57.9 cm, 34d ONO-1301 10 mg/kg 1267.1 ± 53.9 cm; Figure 6 (b). Swimming speed during 4 groups was no significant differences (42d Sham 3.9 ± 0.1 m/s, 42d Vehicle 3.9 ± 0.1 m/s, 42d ONO-1301 10 mg/kg 3.9 ± 0.1 m/s, 34d ONO-1301 10 mg/kg 3.9 ± 0.2 m/s).
Discussion
It has previously been reported that plasma ONO-1301 concentrations after a single subcutaneous administration indicated that its activity would be sustained [14] . In order to investigate the pharmacokinetics of ONO-1301 after oral administration, plasma level of radioactivity derived from 14 C-ONO-1301 were measured after single oral doses of 1 and 10 mg/kg 14 C-ONO-1301 in rats. In both 1-and 10-mg/kg treatment group, the concentration of plasma AUC 0-∞ and C max of 10 mg/kg group were approximately 10-fold greater than the plasma those of 1 mg/kg group. These results suggested that the release profile of ONO-1301 showed a liner model. Liner model is known to easy to repeated treatment. Furthermore, plasma level of radioactivity of ONO-1301 is keep low levels without being zero ng cq./ml 36 h after treatment of ONO-1301. These finding suggested ONO-1301 has possible to accumulate if ONO-1301 was repeated treatment for long term. However, in order to exert maximum neuroprotective effect, we decided ONO-1301 of treatment time is twice a day in this experimental schedule because T 1/2 was about 5 -8 h.
In this study, twice-daily treatment with ONO-1301 [23] [24] [25] . In a previous study, it was reported that the therapeutic window for cannabidiol treatment to delay ischemic damage was determined by its inhibition of the inflammatory reaction, which was divided into three phases. Firstly, MPO-positive cells were expressed on 1 and 3 days after ischemia; secondly, microglia was activated on 1, 3, 7 and 14 days; and thirdly, astrocytes were activated on 7 and 14 days [26] . That is why, rats were treated vehicle for 8 days and ONO-1301 for 34 days. We determined hirtological and behavior change about neuron-protective effect of ONO-1301. The histological changes taking place in the brain tissue were investigated by assessment of PCNA-and GFAP-positive cells. The 42 days ONO-1301 treatment inhibited expression of both PCNA-positive cells and the activated astrocyte reaction induced by repeated cerebral ischemia, while the 34 days ONO-1301 treatment did not inhibit the activated astrocyte reaction. These results suggested that the first 8 days after ischemia-reperfusion is the most important phase in which to inhibit activated astrocytes.
Neutrophil elastase is known to be released from activated neutrophils during the process of inflammation, elastase inhibitors exert a cardioprotective effect against reperfusion injury, probably by inhibition of leukocyte extravasation as indicated by the decrease in myeloperoxidase (MPO) activated within 7 days after ischemia [27] . Neutrophil elastase decreases the endothelial production of PGI 2 through the inhibition of endothelial nitric oxide synthase (NOS) activation and thereby contributes to the development of ischemia-reperfusion-induced liver injury [28] . In these reports, PGI 2 production is being regulated by two opposing effects after ischemia-reperfusion, being increased by noradrenaline and decreased by neutrophil elastase. The results of this study suggest that it is the PGI 2 -agonist effect of ONO-1301, rather than the TXA 2 -inhibitory effect, which is responsible for its neuroprotective effects. The neuroprotective mechanism of ONO-1301 is probably inhibited inframmation reaction of PGI 2 such as suppress the neutrophil elastase activity in the first phase after ischemia-reperfusion, as the histological results showed the 34 days ONO-1301 treatment group to have less effect than the 42 days ONO-1301 treatment group.
Cerebral ischemia induces cell death in the hippocampal CA1 pyramidal neurons, so the number of surviving CA1 pyramidal neurons gives a measure of the neuroprotective effect of ONO-1301. Treatment with ONO-1301 (1 and 10 mg/kg) for 42 days post-ischemia was significantly suppressed neuronal death. We determined behavior change as spatial learning using MWM task. When spatial learning was assessed by the MWM task on the 14 days after the end of the 42 days ONO-1301 treatment period, the goal latency of 42 days ONO-1301-treated rats was significantly improved compared with the vehicle-ischemia group. Furthermore, the swimming time of the 42 days ONO-1301-treated rats was significantly improved compared with the vehicle-ischemia group. While the goal latency and swimming time of 34 days ONO-1301 10 mg/kg treatment group was also significantly improved compared with the vehicle-ischemia group. However, the improvement effect was less than that of the 42 days ONO-1301 treatment group. These results suggest that the critical phase for inhibition of the progressive inflammatory reaction (i.e., the therapeutic window) is less than 8 days after cerebral ischemia. Repeated treatment of ONO-1301 was indicated no affect to swimming ability and safety because swimming speed was no significant difference.
Conclusions
ONO-1301 has been developed as a novel long-acting PGI 2 agonist with thromboxane synthase inhibitory activity. The primary finding of this study was ONO-1301 has neuroprotective effects when administered orally after experimentally induced cerebral ischemia. Daily treatment with oral ONO-1301 for 42 days post-ischemia prevented brain damage by inhibiting activated astrocytes. It was necessary to commence treatment with ONO-1301 within the 8 days period immediately following the ischemic insult. These findings suggest that ONO-1301 may be a clinically useful treatment if used soon after cerebrovascular accident.
